$TELA
TELA Bio Inc

2023 Q4 Form 10-Q Financial Statement

#000155837023018822 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $17.00M $15.05M
YoY Change 46.26% 34.89%
Cost Of Revenue $5.374M $4.660M
YoY Change 55.95% 21.35%
Gross Profit $11.62M $10.39M
YoY Change 42.17% 41.95%
Gross Profit Margin 68.38% 69.02%
Selling, General & Admin $21.22M $18.20M
YoY Change 42.5% 23.79%
% of Gross Profit 182.53% 175.2%
Research & Development $2.685M $2.368M
YoY Change -1.5% 12.65%
% of Gross Profit 23.1% 22.79%
Depreciation & Amortization $158.0K $220.0K
YoY Change -23.67% 7.32%
% of Gross Profit 1.36% 2.12%
Operating Expenses $23.90M $20.57M
YoY Change 35.69% 22.4%
Operating Profit -$12.28M -$10.18M
YoY Change 30.08% 7.32%
Interest Expense -$1.345M $1.334M
YoY Change 14.57% 29.26%
% of Operating Profit
Other Income/Expense, Net $733.0K -$776.0K
YoY Change 15.62% -36.76%
Pretax Income -$12.89M -$10.96M
YoY Change 29.17% 2.3%
Income Tax
% Of Pretax Income
Net Earnings -$12.89M -$10.96M
YoY Change 29.17% 2.27%
Net Earnings / Revenue -75.83% -72.79%
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$0.53 -$0.45
COMMON SHARES
Basic Shares Outstanding 24.49M 24.49M
Diluted Shares Outstanding 24.48M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $46.73M $58.20M
YoY Change 11.21% 7.33%
Cash & Equivalents $46.73M $58.20M
Short-Term Investments
Other Short-Term Assets $2.098M $1.660M
YoY Change 4.12% -12.77%
Inventory $13.16M $14.32M
Prepaid Expenses
Receivables $9.737M $8.070M
Other Receivables $0.00 $0.00
Total Short-Term Assets $71.73M $82.25M
YoY Change 14.86% 11.22%
LONG-TERM ASSETS
Property, Plant & Equipment $1.984M $1.749M
YoY Change 17.95% 0.06%
Goodwill
YoY Change
Intangibles $2.119M $2.214M
YoY Change -15.21% -14.65%
Long-Term Investments
YoY Change
Other Assets $265.0K
YoY Change
Total Long-Term Assets $6.322M $5.065M
YoY Change 16.9% -9.68%
TOTAL ASSETS
Total Short-Term Assets $71.73M $82.25M
Total Long-Term Assets $6.322M $5.065M
Total Assets $78.05M $87.32M
YoY Change 15.02% 9.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.667M $3.091M
YoY Change 8.67% -36.35%
Accrued Expenses $15.30M $12.24M
YoY Change 40.77% 18.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.97M $15.33M
YoY Change 36.8% 0.79%
LONG-TERM LIABILITIES
Long-Term Debt $40.52M $40.36M
YoY Change 1.5% 1.5%
Other Long-Term Liabilities $1.685M $1.068M
YoY Change 36.88% -16.69%
Total Long-Term Liabilities $42.20M $41.43M
YoY Change 2.56% 0.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.97M $15.33M
Total Long-Term Liabilities $42.20M $41.43M
Total Liabilities $59.17M $56.77M
YoY Change 10.49% 0.89%
SHAREHOLDERS EQUITY
Retained Earnings -$320.9M -$308.0M
YoY Change 17.03% 16.58%
Common Stock $24.00K $24.00K
YoY Change 26.32% 26.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.88M $30.55M
YoY Change
Total Liabilities & Shareholders Equity $78.05M $87.32M
YoY Change 15.02% 9.75%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$12.89M -$10.96M
YoY Change 29.17% 2.27%
Depreciation, Depletion And Amortization $158.0K $220.0K
YoY Change -23.67% 7.32%
Cash From Operating Activities -$11.05M -$6.970M
YoY Change 0.58% -8.88%
INVESTING ACTIVITIES
Capital Expenditures $201.0K $140.0K
YoY Change -80.78% -148.28%
Acquisitions
YoY Change
Other Investing Activities $12.00K
YoY Change
Cash From Investing Activities -$189.0K -$140.0K
YoY Change -81.93% -51.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.00K 80.00K
YoY Change -107.76% -99.77%
NET CHANGE
Cash From Operating Activities -11.05M -6.970M
Cash From Investing Activities -189.0K -140.0K
Cash From Financing Activities 17.00K 80.00K
Net Change In Cash -11.22M -7.030M
YoY Change -8.4% -126.4%
FREE CASH FLOW
Cash From Operating Activities -$11.05M -$6.970M
Capital Expenditures $201.0K $140.0K
Free Cash Flow -$11.25M -$7.110M
YoY Change -6.49% -3.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24487578
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19165027
dei Entity Central Index Key
EntityCentralIndexKey
0001561921
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39130
dei Entity Registrant Name
EntityRegistrantName
TELA Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5320061
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Great Valley Parkway, Suite 24
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
320-2930
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TELA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24488803
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58202000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42019000
CY2023Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
8072000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6621000
CY2023Q3 us-gaap Inventory Net
InventoryNet
14323000
CY2022Q4 us-gaap Inventory Net
InventoryNet
11792000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1655000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2015000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
82252000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
62447000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1749000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1682000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2214000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2499000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1102000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1227000
CY2023Q3 us-gaap Assets
Assets
87317000
CY2022Q4 us-gaap Assets
Assets
67855000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3091000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1534000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12243000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10869000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15334000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12403000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40363000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
39916000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1068000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1231000
CY2023Q3 us-gaap Liabilities
Liabilities
56765000
CY2022Q4 us-gaap Liabilities
Liabilities
53550000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24487578
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19165027
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
24000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
338392000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
288361000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
135000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
150000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-307999000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274225000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30552000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87317000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67855000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15052000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11159000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41455000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29796000
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
4568000
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
3745000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
12682000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
10219000
CY2023Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
CY2022Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
709000
CY2023Q3 us-gaap Gross Profit
GrossProfit
10389000
CY2022Q3 us-gaap Gross Profit
GrossProfit
7319000
us-gaap Gross Profit
GrossProfit
28488000
us-gaap Gross Profit
GrossProfit
18868000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14474000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11172000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
42517000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
31605000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3728000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3532000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10834000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10620000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2368000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6934000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6211000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
20570000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
16806000
us-gaap Operating Expenses
OperatingExpenses
60285000
us-gaap Operating Expenses
OperatingExpenses
48436000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10181000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9487000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31797000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29568000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1334000
CY2022Q3 us-gaap Interest Expense
InterestExpense
1032000
us-gaap Interest Expense
InterestExpense
3878000
us-gaap Interest Expense
InterestExpense
2877000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1228000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
558000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-195000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1901000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-644000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-776000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1227000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1977000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4749000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10714000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
us-gaap Net Income Loss
NetIncomeLoss
-34317000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24483664
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24483664
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16758573
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16758573
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22322256
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22322256
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15293094
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15293094
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10714000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
us-gaap Net Income Loss
NetIncomeLoss
-34317000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
133000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
314000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10906000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10581000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33789000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34003000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-361000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1322000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1535000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2291000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
88000
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1369000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30552000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
101000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
88000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
285000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3791000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30552000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1542000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
133000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1027000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34400000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10714000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23301000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20098000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
157000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
314000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2950000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34400000
us-gaap Net Income Loss
NetIncomeLoss
-34317000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23301000
us-gaap Profit Loss
ProfitLoss
-33774000
us-gaap Profit Loss
ProfitLoss
-34317000
us-gaap Depreciation
Depreciation
362000
us-gaap Depreciation
Depreciation
271000
us-gaap Paid In Kind Interest
PaidInKindInterest
447000
us-gaap Paid In Kind Interest
PaidInKindInterest
507000
tela Noncash Loss On Extinguishment Of Debt
NoncashLossOnExtinguishmentOfDebt
1228000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
709000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
33000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
26000
us-gaap Inventory Write Down
InventoryWriteDown
992000
us-gaap Inventory Write Down
InventoryWriteDown
1809000
us-gaap Share Based Compensation
ShareBasedCompensation
3791000
us-gaap Share Based Compensation
ShareBasedCompensation
2950000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1456000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1531000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3503000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6540000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1373000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
799000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
186000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-763000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29806000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29765000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
406000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
826000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-406000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-826000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46341000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34675000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
40000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
30000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3460000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
285000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
157000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
88000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46245000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41071000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-185000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16183000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10295000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42019000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43931000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58202000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54226000
us-gaap Interest Paid Net
InterestPaidNet
3431000
us-gaap Interest Paid Net
InterestPaidNet
2370000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
tela Offering Costs In Accounts Payable And Accrued Expense And Other Current Liabilities
OfferingCostsInAccountsPayableAndAccruedExpenseAndOtherCurrentLiabilities
275000
tela Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
1000000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1376000
tela Tenant Improvements And Deferred Rent Exchanged For Operating Lease Liabilities
TenantImprovementsAndDeferredRentExchangedForOperatingLeaseLiabilities
380000
tela Operating Lease Obligation Assumed
OperatingLeaseObligationAssumed
-1756000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308000000.0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
392000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
165000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1771000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
383000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company’s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p>
tela Incremental Costs Of Obtaining Contract
IncrementalCostsOfObtainingContract
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15052000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11159000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41455000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29796000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3155247
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2404467
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
90000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
366000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
375000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
358000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1413000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1100000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7088000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6420000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2535000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2563000
CY2023Q3 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
1780000
CY2022Q4 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
1263000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
345000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
340000
CY2023Q3 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
217000
CY2022Q4 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
137000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
278000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12243000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10869000
CY2023Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2022Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1637000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2084000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
40363000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
39916000
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
88556
CY2023Q3 tela Equity Incentive Plans Number
EquityIncentivePlansNumber
2
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1369000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1027000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3791000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2950000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2071848
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
212960
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
19556
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
62988
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.18
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2202264
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2163822
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1547113
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0399
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M24D

Files In Submission

Name View Source Status
tela-20230930_cal.xml Edgar Link unprocessable
0001558370-23-018822-index-headers.html Edgar Link pending
0001558370-23-018822-index.html Edgar Link pending
0001558370-23-018822.txt Edgar Link pending
0001558370-23-018822-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tela-20230930.xsd Edgar Link pending
tela-20230930x10q.htm Edgar Link pending
tela-20230930xex10d2.htm Edgar Link pending
tela-20230930xex31d1.htm Edgar Link pending
tela-20230930xex31d2.htm Edgar Link pending
tela-20230930xex32d1.htm Edgar Link pending
tela-20230930xex32d2.htm Edgar Link pending
tela-20230930xex3d1.htm Edgar Link pending
tela-20230930_def.xml Edgar Link unprocessable
tela-20230930_lab.xml Edgar Link unprocessable
tela-20230930_pre.xml Edgar Link unprocessable
tela-20230930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable